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Abstract
Background: Road traffic accidents are known to be the main cause of traumatic brain injury (TBI). TBI is also a
leading cause of death and disability. This study, by means of the idiographic approach (single-case experimental
designs using multiple-baseline designs), has examined whether methylphenidate (MPH - trade name Ritalin) had a
differential effect on cognitive measures among patients with TBI with the sequel of acute and chronic post-
concussion syndromes. The effect on gender was also explored.
Methods: In comparison with healthy controls, patients with TBI (acute and chronic) and accompanying mild
cognitive impairment (MCI) were screened for their integrity of executive functioning. Twenty-four patients
exhibiting executive dysfunction (ED) were then instituted with the pharmacological intervention methylphenidate
(MPH). The methylphenidate was administered using an uncontrolled, open label design.
Results: The administration of methylphenidate impacted ED in the TBI group but had no effect on mood.
Attenuation of ED was more apparent in the chronic phases of TBI. The effect on gender was not statistically
significant with regard to the observed changes.
(Continued on next page)
© The Author(s). 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: samir-adawi@fulbrightmail.org; adawi@squ.edu.om;
drmdessa@gmail.com; wqoronfleh@qf.org.qa
1Department of Behavioural Medicine, College of Medicine and Health
Sciences, Sultan Qaboos University, Muscat, Oman
7Department of Food Science and Nutrition, College of Agricultural and
Marine Sciences, Sultan Qaboos University, Muscat, Oman
9Research & Policy Department, World Innovation Summit for Health (WISH),
Qatar Foundation, P.O. Box 5825, Doha, Qatar
Full list of author information is available at the end of the article
Al-Adawi et al. BMC Neurology          (2020) 20:103 
https://doi.org/10.1186/s12883-020-01663-x
(Continued from previous page)
Conclusions: To our knowledge, this is the first feasibility trial from the Arabian Gulf to report the performance of a
TBI population with mild cognitive impairment according to the IQCODE Arabic version. This investigation confirms
anecdotal observations of methylphenidate having the potential to attenuate cognitive impairment; particularly
those functions that are critically involved in the integrity of executive functioning. The present feasibility trial
should be followed by nomothetic studies such as those that adhere to the protocol of the randomized controlled
trial. This evidence-based research is the foundation for intervention and future resource allocation by policy- or
public health decision-makers.
Keywords: Psychopharmacology, Executive functioning, Traumatic brain injury, TBI, Cognition, Depression, Anxiety,
IQCODE, Methylphenidate, Ritalin
Background
At least 1 million people from all across the world sus-
tain traumatic brain injury (TBI) each year [1]. Accom-
panying this statistic is an increasing recognition that
TBI is a leading cause of death and disability [2–4] as
well. Importantly, TBI typically seems to impact individ-
uals under the age of 45, a prime age for maximum hu-
man productivity [5]. Considering this fact, the situation
is likely to be even more critical to the World Health
Organization (WHO) classified ‘Eastern Mediterranean’
country of Oman, where 88.6% of the country’s popula-
tion falls within this age group [6].
In many Eastern Mediterranean countries, including
Oman, road traffic accidents are known to be the main
cause of TBI. It is estimated that road traffic accidents
account for about 42 to 95% of all reported TBI cases.
They are also a leading reason for death [7]. Each year,
approximately 300 to 400 per 100,000 people in Oman
suffer from TBI [7], translating roughly to a rate of 17 to
23 people per day. In a survey conducted by the Omani
Ministry of Health [8], about 116 of the 17,791 individ-
uals surveyed were involved in a “serious accident” in the
preceding year. Approximately 11% of the 116 subjects
were admitted to a hospital “for a long period”, and at
least 1.2% currently live with varying degrees of physical
handicaps, including disability. Consequently, there has
been growing interest in the field of disabilities and re-
habilitation amongst brain-injured populations. In
addition to various physical complications, a significant
number of these patients struggle with cognitive impair-
ments, particularly impairment of executive function [9],
indicated to have poor prognostic indicators compared
to those with amnesiac features [10]. However, there is a
dearth of studies reporting this problem conducted in
the Eastern Mediterranean despite the high rate of ac-
quired brain injuries in the region [11].
Research from other populations have revealed that
executive functioning can be manipulated by agents hav-
ing an affinity for dopaminergic and noradrenergic sys-
tems [12–14]. In this regard, one of the most commonly
used agents are methylphenidate (MPH-Ritalin): a
neuro-stimulant postulated to increase synaptic dopa-
mine and noradrenaline levels by blocking their re-
uptake, accordingly, heightening information processing
[15]. Emerging views suggest a neurobiological and
neurochemical basis for executive functioning involving
the cortico-striatal-thalamo-cortical circuits [16, 17], as
well as dopaminergic and noradrenergic systems [18,
19]. In support of this explanation, preclinical animal
studies have shown that disrupting catecholaminergic
projections to the frontal cortex results in deficits in
working memory and executive functioning [20]. Dam-
age to the frontal cortex may be expressed as impair-
ments in working memory, self-directed, executive,
cognitive functions including the reduction in the speed
of information processing and concentration. The effects
of frontal impairments due to TBI are pervasive as re-
habilitation and quality of life (QoL) are likely to be im-
pacted by cognitive deficits rather than overt physical
disabilities.
Studies from developed countries show that the ‘vic-
tim’ of TBI tends first to receive critical care and later
undergo neurorehabilitation in dedicated units where
neuro-stimulants are instituted depending on the clinical
and cognitive symptoms [4]. While neuro-stimulants are
widely used to tease out their impact functional recovery
[12–14], with few exceptions, there is a scarcity of stud-
ies shedding light on when is the most optimal time to
commence initiation of neuro-stimulants. In the litera-
ture, the time elapsed since the injury is often reported
to have been shown to range from a day to several years
after initial TBI injury [21, 22]. There is no description
of whether the participants were treated with methyl-
phenidate during an acute or chronic post-TBI phase.
Kaelin, Cifu & Matthies [23] have operationalized
acutely brain-injured adult those whose time since injury
is approximately 2 months. Studies are therefore needed
to shed light on whether acute (≤ 2 months) or chronic
phase (≥ 2 months) is more responsive to neuro-
stimulants.
In a TBI animal model, female sex hormones have been
indicated to be critically involved in the modulation of
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dopaminergic and noradrenergic systems [24]. This would
imply that there are likely to be a gender-specific response
to compounds that have an affinity to dopaminergic and
noradrenergic activities such as methylphenidate. In the
clinical literature, investigations have suggested that there
are gender-specific responses to methylphenidate [25, 26],
but these studies are limited to non-TBI clinical popula-
tions. There is a lack of studies that have examined
whether there are gender-specific responses to methyl-
phenidate in the TBI population in the Eastern Mediterra-
nean region and Oman is no exception. With the
aforementioned literature review, this study has embarked
to address the following aims: (i) to quantify whether
treatment with methylphenidate improves executive func-
tioning and mood in Omani patients with TBI and mild
cognitive impairment and executive dysfunction, (ii) to
measure the effect of methylphenidate on executive func-
tioning and mood in acute or chronic phases of TBI, and
(iii) to explore if the administration of methylphenidate
and gender has a direct bearing on whether the patient is
in the acute vs chronic phase. Previous studies have teased
out the role of methylphenidate and cognitive enhance-
ment. Most of the research on the TBI population are
marred by a highly heterogeneous sample in the midst of
heterogeneity of clinical and neuroimaging data [12, 13,
19, 21, 23]. This investigation is, therefore, constitute a
feasibility trial with well defined executive dysfunction
profiles that employed the idiographic approach, which is,
single-subject experimental research designs using
multiple-baseline designs (AABAA) that is equipped to
accommodate the diversity and complexity of the TBI
population [27].
Methods
Setting
Tertiary care is largely compartmentalized and central-
ized in Oman. The study sample consisted of Omani pa-
tients up to the age of 35 years who had sustained TBI
and were referred to state-run tertiary care facilities at
Sultan Qaboos University Hospital and Khoula Hospital
for evaluation and treatment. Patients with TBI were
prospectively enrolled between October 2015 and De-
cember 2016. The present study, therefore, constitutes a
feasibility trial among TBI patients who were clinically
evaluated as being amenable to routine pharmacological
intervention.
Participants
For ethical approval see the such annotated section
below for further consent and trial details. Also, Fig. 1
Fig. 1 Flow diagram of study participants
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shows the study flowchart. Participants were identified
clinically as being marked with cognitive impairment
and presented pervasive impairment in learning and
memory both in therapy and in their daily lives. The
study inclusion criteria included participants with a doc-
umented history of a single TBI incident. TBI is defined
here, as an injury to brain tissues caused by an external
mechanical force, evidenced by a loss of consciousness,
post-traumatic cognitive and behavioral changes or an
objective neurological finding that can reasonably be at-
tributed to the TBI on a physical or cognitive and behav-
ioral status examination [28]. The second inclusion
criteria are availability time since injury and other clin-
ical risk factors as detailed in Table 1. The third inclu-
sion criteria are participants fulfilling the criteria of mild
cognitive impairment that would be selected via object-
ive measure. The fourth inclusion criteria are that the
participants manifest executive dysfunction. This was
quantified using established neuropsychological mea-
sures where their percentile scores are ≤7 in the execu-
tive functioning batteries. Executive functioning is a
cognitive process that involves planning, decision mak-
ing, error correction and troubleshooting [29]. It also in-
volves situations where responses are not well-rehearsed,
situations that require novel sequences of actions, and
that require the overcoming of a strong habitual re-
sponse or resisting temptation. Another final study in-
clusion is complete baseline data on the “Capacity to
Consent to Treatment Instrument” [30].
Exclusion criteria include those with cognitive symp-
toms that are not directly attributable to the acquired
brain injury. Similarly, the exclusion criterion included
pre-injury, psychiatric or neurological histories other
than those resulting from TBI and those presently on
anti-seizure medication.
Assessment of cognitive and affective ranges
Cognitive functioning: mild cognitive functioning
The presence of mild cognitive impairment was solicited
via a validated Arabic version of the Informant Question-
naire on Cognitive Decline in the Elderly (IQCODE)
[31]. As per established protocol, the accompanying
family, who had been living with the respondent, was
asked to fill out the IQCODE [31]. The items in the
IQCODE require the family member to identify what
the individual was like before the TBI incident and to
compare that with what the person is like now. The
IQCODE is equipped to screen for the variation in cog-
nitive functioning, which in turn suggests the presence
of cognitive decline. The IQCODE-16 utilized the fol-
lowing scoring system: ‘major improvement’ = 1, ‘minor
improvement’ = 2, ‘did not change much’ = 3, ‘minor de-
terioration’ = 4 and ‘major deterioration’ = 5 [32]. For the
present study, only patients with TBI endorsed to have
‘minor deterioration’ were included. Existing literature
shows that ‘minor deterioration’ in IQCODE denotes
mild cognitive impairment. The IQCODE has been
established with high accuracy to identify the presence
of mild cognitive impairment similar to other well-
established examinations [33, 34].
Cognitive functioning: executive functioning
In the neuropsychological literature, the Wisconsin
Card-Sorting Test, Tower of London and Trail Making
Test are all considered essential for assessing some of
the broader domains of executive dysfunction [35]. The
modified Wisconsin Card-Sorting Test was used to gauge
“set-shifting” and cognitive flexibility via two sub-scales:
“Number of Categories Completed” and “Preservative
Errors”. The protocol for administering and scoring this
test has been detailed in prior studies [36]. The Tower of
London Test was employed to detect deficits in planning
and the temporal organization of behavior [29, 37]; ad-
ministration and scoring of this test have also been de-
tailed in other studies [30, 38]. Lastly, the Trail Making
Test was used to tap into cognitive processing speed, an
integral part of executive functioning [39]. The scoring
for the Trail Making Test was derived from two versions
of the test, which were described elsewhere [35].
Digit Span (Wechsler Adult Intelligence Scale Sub-
test) is a scale with two components: Digits Forward and
Digits Backward [40]. In the present context, only Digits
Backward was employed; here the participant was read a
random series of numbers and asked to repeat them in
the reverse order (e.g., 9–1-3, should be repeated as 3–
1-9). There is evidence to support the notion that Digits
Backward rather Digits Forward is relevant to the integ-
rity of executive functioning [41–43].
Table 1 Comparative assessment of executive functioning between traumatic brain injured Omani patients having mild cognitive
impairment and healthy controls (n = 49)
Instrument TBI (n = 24) Control(n = 25) P-value
Executive Functioning Total score of Trail Making Test 156.75 ± 76.4 90.16 ± 13.29 < 0.0001
Categories completed from Wisconsin Card Sorting Test 1.50 ± 0.72 3.72 ± 0.46 < 0.0001
Perseverative errors from Wisconsin Card Sorting Test 17.42 ± 6.14 3.12 ± 3.44 < 0.0001
Tower of London 10.00 ± 4.86 19.64 ± 5.35 < 0.0001
Analyses were conducted using student’s t-test
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Verbal Fluency (The Controlled Oral Word Associ-
ation Test) [44] examines the initiation and speed of ver-
bal responses. Participants were asked to produce as
many different words that begin with three specific let-
ters as possible, with one minute allowed per letter. Sub-
jects were explicitly told not to repeat the same word
twice, and not to use words that share a common root
with a previously mentioned word (for example, fish,
fishing, fisherman). Following these instructions, an ex-
ample and a demonstration were provided so that the
participants understood the task requirements, after
which he/she was given each letter in turn. The total
score for Verbal Fluency is the total number of different
acceptable words produced across the three 60-s periods
[36]. In this experiment, the letters consisted of taa, raa,
and waaw from the Arabic alphabet, as described in
prior research [45]. The efficiency of verbal fluency has
been linked to the integrity of the dorsolateral prefrontal
cortex [46, 47].
Affective ranges: anxiety and depressive symptoms
In order to rule out whether methylphenidate had a spe-
cific impact on executive functioning, the Hospital Anxiety
and Depression Scale (HADS) [48] was administered to as-
certain whether changes in the other measures were paral-
leled by alteration in anxiety and depression. The scale is a
questionnaire composed of 14 items of which seven relat-
ing to depression while the other seven relating to anxiety.
The psychometric properties of HADS were previously re-
ported in the Omani population [49, 50].
Socio-demographic and clinical risk factors
In addition to cognitive and affective ranges, various
socio-demographic and clinical data were sought from
the medical records or from the accompanying family
member(s) or the patients themselves including gender,
age, education (‘still in educational setting’, ‘completed
college’, ‘some college’, ‘secondary’, ‘primary’), injury se-
verity using Glasgow Coma Scale [51] (GCS; ‘mild = 13
to 15’, ‘moderate = 9 to 12’, ‘severe = less than 9’), and
causes of TBI (‘road traffic accident’, ‘fall’). The presence
of neuropathology if any were reported in terms of brain
scans (computerized tomography-CT and magnetic res-
onance imaging-MRI). The time since injury was also
sought, which as defined as acute (< 2 months since the
TBI) or chronic (≥ 2 months since the TBI) [52–56].
Quantification of mild cognitive functioning and
executive dysfunction
In Oman and Arabic speaking population in general,
there are no established measures to establish the pres-
ence of executive dysfunction. Therefore, the protracted
exercises were needed to establish the presence of ex-
ecutive dysfunction. For quantification of mild cognitive
impairment, the Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE), was used. As shown in
Fig. 1, IQCODE identified 106 out of 118 to meet the se-
lection criteria for mild cognitive impairment.
The recognized 106 patients they were further scruti-
nized for the presence of executive functioning via their
performance on the Wisconsin Card-Sorting Test, Tower
of London Test and Trail Making Test that are known to
be the sine-qua non for assessing executive functioning.
Healthy volunteers were therefore recruited in order to
establish the extent to which the TBI subjects with mild
cognitive impairment ‘deviated’ from the healthy control
group. The control population was recruited from
amongst the staff of Sultan Qaboos University-SQU (n =
25). The healthy controls were matched for age, gender,
and education. Inclusion for the control group included
those with no history of medical, psychiatric or neuro-
logical conditions that warranted medical attention. This
was orally confirmed for all consenting participants.
In order to quantify whether the TBI group exhibited
executive dysfunction, z-values were computed for both
the TBI and healthy control cohorts. Domain scores for
each subject were calculated based on the mean test re-
sults of all tests from the respective domain. As detailed
in other studies [29], tests were defined as indicating
cases of executive dysfunction if the z-value was less
than − 1.5. A domain was judged as pathological if more
than half of the included tests of the respective domain
showed z-values below − 1.5 or percentile <7th. Table 2
highlights significant differences between the TBI group
and the control group on the four administered tests for
assessment of Executive Functioning (Trail Making Test,
Tower of London Test and two sub-scales of the Wiscon-
sin Card Sorting Test). In the Trail Making Test, the
control group had an average of 90 s (SD = 13), while the
TBI group took substantially longer (average of 157 s
(SD = 76) to complete the task (p < 0.001). In the Wis-
consin Card Sorting Test, “Number of Categories Com-
pleted” and “Preservative Errors” were determined. In
the former, TBI patients completed only 1.5 categories
on average, which is significantly less than the control
group who completed an average of 3.7 categories (p <
0.001). The patient group also had significantly more
“Preservative Errors” compared to the control (17 vs 3;
p < 0.001). In the Tower of London Test, the control
group scored nearly twice as high as the TBI patients
(19.6 vs 10; p < 0.001) (Table 1). Therefore, as shown in
Fig. 1, the participants with TBI (n = 49) met operation-
alized criteria of executive dysfunction.
Protocol for a feasibility trial
Participants with TBI (n = 32) with z-values below − 1.5
were deemed to suit the study criteria for feasibility trial
with methylphenidate (MPH) using AABAA single-case
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methodology as depicted below graphically (Table 3).
The methylphenidate was administered using an uncon-
trolled, open label design which is explained below.
The assessments were conducted at baseline after the
maximum dose of methylphenidate was instituted and
the withdrawal of methylphenidate. Both Digit Span and
Verbal Fluency circumvent the issue of practice or learn-
ing effect owing to the availability of various versions of
these two measures and hence were used for successive
assessments of the TBI patients. The baseline (BL) per-
formance on cognitive measures constituted the average of
two consecutive scores of the Digit Span and Verbal Flu-
ency and similarly, the average of post-methylphenidate
withdrawal (POST) performances was considered. The
cognitive performance scores at a maximum dosage of me-
thylphenidate were considered only once. Hospital Anxiety
and Depression (HADS) was utilized to solicit the varia-
tions in anxiety and depression symptom in parallel with
cognitive measures.
For the purpose of analysis of their responses, the pa-
tients were divided into two groups based on the time
elapsed since the injury. Those whose time since injury
was less than two months were operationalized as ‘acute’
TBI and the rest were operationalized as ‘chronic TBI’
[52]. The basic single-case methodology (AABAA)
adopted was a repeated measure, with multiple baselines
as shown above schematically. The second baseline as-
sessments (A) was one week after the first baseline (A)
and then (B) instituting methylphenidate (the starting
dose was 5 mg/day, increasing to a maximum dosage of
10 mg/day). The assessment (B) took place when partici-
pants were in methylphenidate, that is, 30 days after the
second baseline. Follow-up evaluations (POST1) were
Table 2 Clinical and demographic characteristics of traumatic brain injured Omani participants with mild cognitive impairment and
executive dysfunction
Parameter No. of Patients % of Patients
Gender Male 13 54.2
Female 11 45.8
Age 18–25 17 70.8
26–35 7 29.2
Education Still in Educational setting 5 20.8
Completed College 3 12.5
Some College 2 8.3
Secondary 11 45.8
Primary 3 12.5
Injury severity Unknown 3 12.5
GCS (mild; 13 to 15) 5 20.8
GCS (moderate; 9 to 12) 15 62.5
GCS (severe; less than 9) 1 4.2
Causes of Traumatic Brain Injury Unknown 2 8.3
Road Traffic Accident 20 83.3
Fall 2 8.3
Time since injury Acute (< 2 months) 9 37.5
Chronic (≥ 2 months) 15 62.5
Neuropathology (CT or MRI) Diffused 6 25
Bilateral Frontal Hematoma 12 50
Focal 6 25
CT = Computed Tomography Imaging; MRI =magnetic resonance imaging; GSC = Glasgow Coma Scale
Table 3 Protocol design for the administration of
methylphenidate that followed AABAA single case
methodology
A Baseline 1 (BL1)
*A Baseline 2 (BL2)
**B Maximum dose of methylphenidate (MAXMETH)
***A Post-withdrawal 1 (POST1)
***A Post-withdrawal 2 (POST2)
* BL2 evaluations conducted over 15 days of BL1 and then the institution of drug
treatment (the starting dose was 5 mg/day, increasing to a maximum dosage
of 10 mg/day)
** MAXMETH evaluations conducted at 30 days after BL2
*** Follow-up evaluations (POST1) were conducted at 15 days after the MAXMETH
evaluation while POST2 was conducted after 15 days after POST1
Al-Adawi et al. BMC Neurology          (2020) 20:103 Page 6 of 14
conducted at 15 days after the MAXMETH evaluation
while POST2 was conducted after 15 days after POST1.
Statistical analysis
Statistical analysis was performed using SPSS Version
19. Summary tables were produced. t-tests and repeated
ANOVA tests were used and p-values were reported in
the tables.
Ethical approval, trial withdrawal and discontinuation of
trial medication
This study was approved by the Institutional Review
Board, ‘Ethical Committee for Human and Clinical Re-
search’ and the ‘Medical Research Committee’ (Project
No. MED 99–4) of of the College of Medicine & Health
Sciences, Sultan Qaboos University (SQU). Participants
were requested to provide written informed consent
which was also confirmed verbally again prior to data
collection, and the study procedures were carried out in
accordance with the Code of Ethics of the World Med-
ical Association (Declaration of Helsinki of 1964–2008)
for human experiments including confidentiality, priv-
acy, documentation and data management. As for the
trial withdrawal and discontinuation of trial medication,
participants were explicitly informed that they are free
to withdraw from the trial at any time without reason or
impact on usual care. As shown in Fig. 1, only data from
completed cycles were included in the analysis.
Results
Table 2 details clinical and demographic information of
the TBI patients identified as having executive dysfunc-
tion (Fig. 1 provides the flowchart). Of the 32 patients,
24 completed the study (11 were female and 13 were
male), however, 8 were lost at follow-up and/or stopped
participation. Out of the 8, 4 could not tolerate the
medication. The majority had received education up to
secondary school and above (n = 21). In terms of severity
of the injury, 15 patients had moderate scores and 5 had
mild scores on the Glasgow Coma Scale [57]. Neuro-
imaging data indicated that 25% (n = 6) of the TBI group
exhibited characteristics of diffused and focal brain in-
juries respectively, while 50% (n = 12) had frontal
hematoma. Road traffic accidents were the major cause
of TBI in this group (20 out of 24). Almost 63% of the
cases were chronic cases. Nearly 50% had bilateral
frontal hematoma as evidenced by computed tomog-
raphy imaging or magnetic resonance imaging.
Further assessments of all TBI patients using stable
cognitive measures (Verbal Fluency, Digit Span) and
affective measures (anxiety and depression) across differ-
ent time periods in comparison to baseline values are
shown in Table 4. There was a significant rise in Digit
Span results. A baseline reading of 4.00 (SD 0.81)
increased to 5.71 (SD 0.81) following the administration
of methylphenidate. The scores remained high at 5.88
(SD 1.87), post-methylphenidate withdrawal (p < 0.001 in
both situations). Verbal Fluency similarly exhibited a sig-
nificant increase from the baseline score (9.33, SD 2.98)
to scores obtained during methylphenidate treatment
(12.38, SD 3.41; p < 0.001) and post-withdrawal scores
(12.21, SD 4.31; p = 0.008).
The average HADS–Depression score of 7.02 (SD
2.63) at baseline decreased to 6.50 (SD 2.69) with me-
thylphenidate administration (p = 0.033) but showed no
significant change post-methylphenidate withdrawal with
a score of 6.54 (SD 2.89) (p = 0.150). There was no sig-
nificant change in the baseline result of anxiety (6.77, SD
3.45) from the results obtained after methylphenidate
administration (6.88) and post-withdrawal (6.67).
Table 5 and Table 6 describe raw scores to examine
whether acute (< 2months) or chronic phases of TBI (≥ 2
months) had any effect on executive functioning and
mood after administration and later withdrawal of methyl-
phenidate. Nine patients were in the acute phase of TBI
during the study, these were seen less than two months
after injury (four males and five females), and 15 were in
the chronic phase of TBI, they were seen two or more
months after the injury (nine males and six females).
Based on their scores, both groups showed improvement
in executive functioning following methylphenidate inter-
vention. When executive functioning was assessed post-
withdrawal, it was found that the acute group reverted to
their original baseline scores, while the chronic group
maintained the improved scores. Detailed analysis re-
vealed that the TBI phase (i.e. acute vs chronic) had a sub-
stantial effect on executive functioning (Digit Span and
Verbal Fluency), especially after correcting for baseline
values (Table 7). Digit Span and Verbal Fluency scores
were significantly higher than post-withdrawal scores for
the chronic group, implying that methylphenidate en-
hanced executive functioning. The changes in HADS–De-
pression and HADS–Anxiety across the two TBI phases
were not significant (Table 7).
Gender did not contribute to any significant difference
in the scores of executive functioning and mood during
methylphenidate treatment and after its withdrawal
(Table 8).
Discussion
This feasibility trial has specifically employed the idio-
graphic approach due to the nature of the TBI popula-
tion whereby accruing a large sample size with the stable
and homogeneous clinical data for neuropsychological
evaluation and the pharmacological challenge is often
untenable [58]. Such a cohort is, therefore, more apt to
be studied using idiographic than a nomothetic ap-
proach. For example, as for the present cohort, 20% of
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the patients were mild TBI and 62.5% were classified as
moderate. In addition, only one patient experienced a se-
vere TBI status. It is worth mentioning, that each injury
level has a distinctly different prognosis and presentation
by CT/MRI. Moreover, 37% of the patients were in the
acute phase while 63% were in the chronic phase of in-
jury. This feasibility trial explored three interrelated
themes using idiographic–AABAA single experimental
design.
The first aim was to investigate whether a sample of
TBI patients would perform differently on measures of
executive functioning when compared to a healthy
population in Oman. Attributes that are most often
viewed as defining a human being (e.g., reasoning, tem-
poral organization of behavior, self-regulation, mental
flexibility, aspects of attention and awareness) are some
of the primary constituents of executive functioning.
Furthermore, there is extensive empirical literature sug-
gesting that executive dysfunction is one of the most
debilitating and intransigent aspects of cognitive impair-
ment typically acquired during traumatic brain injury
[59, 60]. To our knowledge, this is the first feasibility
Table 4 Measures of executive functioning (Verbal Fluency, Digit Span) and affective measures (HADS-Hospital and Depression Scale)
across assessment occasions (baseline, during methylphenidate and post-withdrawal of methylphenidate) among a sample of
Omanis with traumatic brain injury
Category Measure Assessment Min Mean Max Std. Dev p
Executive Functioning Digit Span Average baseline 3 4.00 6 0.81
with methylphenidate 4 5.71 7 0.81 p < 0.001
Average Post withdrawal 3 5.88 8 1.87 p < 0.001
Verbal Fluency Average baseline 3 9.33 16 2.96
with methylphenidate 7 12.38 18 3.41 p < 0.001
Average Post withdrawal 5 12.21 19 4.31 P = 0.008
Affective measures HADS-Depression Average baseline 2 7.02 13 2.63
with methylphenidate 2 6.50 13 2.69 p = 0. 033
Average Post withdrawal 2 6.54 13 2.89 p = 0. 150
HADS-Anxiety Average Baseline 2 6.77 15 3.45
with methylphenidate 2 6.88 15 3.31 p = 0.732
Average Post withdrawal 2 6.67 15 3.31 p = 0.719
*All comparisons indicated were with the baseline assessments
Table 5 Descriptive statistics of executive functioning (Digit Span, Verbal Fluency) among a sample of Omanis with traumatic brain
injury and accompanying mild cognitive impairment between time since injury and across different assessment periods based on
gender
Executive functioning Time since injury Baselinea
Mean, SD
Methylphenidateb
Mean, SD
Post withdrawalc
Mean, SD
Digit Span Total < 2 months 3.67 ± 1.00 5.22 ± 0.83 3.67 ± 0.71
≥ 2 months 4.20 ± 0.86 6.00 ± 0.65 7.20 ± 0.68
Females < 2 months 3.60 ± 1.34 5.40 ± 0.89 3.80 ± 0.84
≥ 2 months 4.00 ± 1.09 6.00 ± 0.89 7.17 ± 0.75
Males < 2 months 3.75 ± 0.05 5.00 ± 0.82 3.50 ± 0.58
≥ 2 months 4.33 ± 0.70 6.00 ± 0.50 7.22 ± 0.68
Verbal Fluency Total < 2 months 10.00 ± 2.60 12.44 ± 2.83 8.00 ± 1.66
≥ 2 months 9.07 ± 3.30 12.33 ± 3.81 14.73 ± 3.28
Females < 2 months 8.80 ± 2.05 11.60 ± 2.97 7.80 ± 1.09
≥ 2 months 8.33 ± 3.61 11.00 ± 3.41 13.50 ± 4.18
Males < 2 months 11.50 ± 2.65 13.50 ± 2.65 8.25 ± 2.36
≥ 2 months 9.56 ± 3.20 13.22 ± 3.99 15.56 ± 2.45
a Averages score across two baseline assessments
b Average scores across two post-intervention assessments
c The starting dose was 5 mg/day, increasing to a maximum dosage of 10 mg/day
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trial from the Arabian Gulf to report the performance of
a TBI population with mild cognitive impairment per-
forming poorly on measures of executive functioning
compared to a healthy control group, according to an
Arabic version of Informant Questionnaire on Cognitive
Decline in the Elderly (IQCODE) [32]. In prior studies,
there has been a debate on whether mild cognitive im-
pairment is a prodromal stage of neurogenerative disor-
ders or ‘normal’ variation of cognitive functioning [61].
In the general population, the constituent of mild cogni-
tive impairment has been postulated to include ill-
defined memory impairment, intact global cognitive and
intellectual capacity and no overt symptoms of dementia
[62]. This feasibility trial suggests that in a TBI popula-
tion, there is impairment of executive functioning
among those who fulfilled the criteria of mild cognitive
impairment, a view previously noted by others [63, 64].
Huang et al. [58], in their meta-analysis, have identi-
fied 683 published studies that have reported the use of
methylphenidate for the TBI population from electronic
databases. These studies employed the spectrum of
cognitive measures. The authors concluded that methyl-
phenidate has the potential to mostly enhancing
attentional capacity but not memory or processing
speed. There have been indications that some pharmaco-
logical approaches may be useful in addressing aspects
of executive dysfunction [65, 66], but no studies have
been forthcoming from the Eastern Mediterranean. This
feasibility trial suggests that treatment with the catechol-
aminergic agonist, methylphenidate, impacted executive
dysfunction. Averaging across all participants, methyl-
phenidate treatment did not produce any significant
changes in mood, suggesting that pharmacological inter-
vention impacted cognitive functioning directly rather
than via the patients’ affected state. Discussions in the
current literature on whether cognitive functioning is in-
fluenced by mood or, conversely, whether the mood is
influenced by the level of cognitive functioning, are on-
going [67, 68]. This interpretation is consistent with sys-
tematic and meta-analytic reviews suggesting the lack of
effectiveness of methylphenidate in mitigating symptoms
of depression [69]. It is worthwhile to note that mood
state was measured using the ‘symptom checklist’,
HADS. Future studies should employ more robust mea-
sures such as a semi-structured diagnostic interview, the
‘gold standard’.
Table 6 Descriptive statistics of affective functioning (HADS-Hospital Anxiety and Depression Scale) among a sample of Omanis with
traumatic brain injury suffering from mild cognitive impairment between time since injury and across different assessment periods
based on gender
Affective functioning Time since injury Baseline
Mean, SD
Methylphenidate
Mean, SD
Post withdrawal
Mean, SD
HADS -
Depression
Total < 2 months 7.90 ± 3.73 7.33 ± 3.35 6.78 ± 4.05
≥ 2 months 6.50 ± 1.61 6.00 ± 2.17 6.4 ± 2.06
Females < 2months 5.20 ± 2.59 5.20 ± 2.49 4.40 ± 2.88
≥ 2 months 6.0 ± 1.41 5.67 ± 2.06 5.83 ± 1.32
Males < 2months 11.25 ± 1.26 10.00 ± 2.16 9.75 ± 3.40
≥ 2 months 6.67 ± 1.73 6.22 ± 2.33 6.78 ± 2.44
HADS -
Anxiety
Total < 2 months 5.44 ± 3.64 6.00 ± 3.35 5.89 ± 3.48
≥ 2 months 7.40 ± 3.31 7.40 ± 3.29 7.13 ± 3.22
Females < 2months 5.40 ± 3.78 6.40 ± 3.13 6.20 ± 3.42
≥ 2 months 9.00 ± 3.95 8.50 ± 3.62 8.50 ± 3.62
Males < 2months 5.50 ± 4.04 5.50 ± 4.04 5.50 ± 4.04
≥ 2 months 6.33 ± 2.50 6.67 ± 3.04 6.22 ± 2.77
Table 7 Effect of Methylphenidate on Executive (Digit Span and Verbal Fluency) and Anxiety and Depression tapped by Hospital
Anxiety and Depression Scale (HADS)
Classification During the treatment period Post withdrawal period
P-value* using the baseline as covariate
Digit Span 0.051 ≤0.001
Verbal Fluency 0.334 ≤0.001
HADS - Depression 0.933 0.169
HADS - Anxiety 0.625 0.415
P-values for comparisons over the time since injuryand Depression Scale (HADS) across gender
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The TBI population in Oman has had no access to
dedicated restorative therapies [70]. An enduring theme
in prior studies is the tendency for a majority of brain-
injured patients to recover spontaneously. Another issue
is the establishment of a window of recovery for cogni-
tive impairment. Therefore, deciphering when to inter-
vene is imperative. This feasibility trial indicates that
time since the injury has an effect on cognitive measures
(Digit Span and Verbal Fluency). These measures appear
to have been robustly affected in the “chronic” cohort.
In contrast, the performance on affective measures has
little bearing on whether the participants belong to the
“acute” or “chronic” group. Furthermore, the observed
improvement with methylphenidate administration was
maintained after withdrawal in only the “chronic” group,
but not the “acute” group. This essentially seems to sug-
gest that the administration of methylphenidate is more
effective for the “chronic” group. This raises the question
as to whether the improvement in cognitive function
scores can be attributed to the effect of methylphenidate,
or whether it is simply part of spontaneous recovery.
Despite such a caveat, the consistent baseline scores and
sudden improvement found only after pharmacological
intervention suggest that the improvements were indeed
attributed to chronicity and methylphenidate. Future
studies might explore when it is optimal to use methyl-
phenidate on a TBI population.
In prior work, there has been a dearth of studies
examining the trajectory of time since injury, interven-
tion, and outcome in TBI. What constitutes acute or
chronic is sometimes inferred in terms of ‘primary’ and
‘secondary injury’ [53]. Primary injury has been opera-
tionalized as a time period immediately following injury
[54]. Secondary damage is characterized by complica-
tions starting within minutes, hours, days or even
months after primary injury and includes different
events such as changes in gene expressions, inflamma-
tion, ischaemia, central immunomodulation disturbance,
impaired energy metabolism and neuronal death [55,
56]. These variations of such a cascade of pathological
processes have a direct bearing on the functional out-
come [71]. There is some evidence to suggest that sec-
ondary injury may not be triggered directly by trauma,
but rather a combination of primary injury and the re-
sultant array of pathological processes. A clear-cut de-
marcation between primary and secondary injury has yet
to be established. Undoubtedly, tudies to define what
constitutes acute and chronic phases of TBI are needed.
As this feasibility trial suggests, such demarcation might
lead to prognostic indicators of when neuro-stimulants
are used.
Previously, females have shown have poorer prognostic
indicators and recovery compared to males [72]. This
feasibility trial ostensibly discounts the issue of gender in
executive functioning. The findings suggest no signifi-
cant difference between male and female patients on all
measures. Furthermore, it appears that methylphenidate
has the potential to attenuate symptoms of executive
dysfunction in both genders. Some studies shedding light
on how and why methylphenidate works on executive
functioning have emerged. Methylphenidate has been
suggested to trigger modulation of the catecholaminergic
system or specifically, its capability to attenuate reuptake
of dopamine and norepinephrine neurotransmission in
the brain [19]. Interestingly catecholaminergic neuron
has been shown to innervate cortical and subcortical re-
gions thought to be critically involved in executive func-
tioning in primates [73]. In human beings, compounds
with affinity to the catecholaminergic system such as
methylphenidate have been shown to heighten executive
functioning and its neural substrate in the human brain
[64]. Thus, reflecting on prior scholarly work, the
present finding largely supports the previous contention
that executive functioning can be manipulated with
compounds that affect dopaminergic and noradrenergic
systems [74–76].
An important finding in the present feasibility trial
was that the improvement did not reverse following drug
withdrawal. Although this feasibility trial was not
equipped to investigate the issue of pharmacologically
induced neuroplasticity, there are some anecdotal and
clinical observations indicating that neuro-stimulants,
such as methylphenidate, have had the capacity to “kick-
start” spontaneous recovery [36]. One opinion suggests
brain injury triggers the cascade of excitotoxity [77, 78].
Interestingly, there is evidence to propose that such
Table 8 Effect of Methylphenidate on Digit Span and Verbal Fluency (Executive) and Anxiety and Depression from Hospital Anxiety
and Depression Scale (HADS) across gender.
Classification During the treatment period Post withdrawal period
P-value* using the baseline as covariate
Digit Span 0.677 0.895
Verbal Fluency 0.400 0.237
HADS - Depression 0.492 0.614
HADS - Anxiety 0.891 0.824
*P-values for comparing males against females
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excitotoxity can be ‘scavenged’ by the catecholaminergic
system [79, 80], for example, when methylphenidate is
exogenously induced [77, 81].
Limitations
Despite that non-parametric statistics were utilized to
observe changes across baseline, intervention and post-
withdrawal periods, some limitations of the feasibility
trial ought to be highlighted. First and foremost, this
feasibility trial is limited by being an open-label study
(i.e., not double blinded and with no control group), a
cohort with homogeneity of injuries and a relatively
small sample size. Despite fulfilling the requirement of
the idiographic study, when a feasibility trial is scruti-
nized under the prism of the nomothetic microscope,
are likely to be seen with several limitations. Therefore,
this feasibility trial should lay the groundwork for ran-
domized clinical trials. Secondly, this feasibility trial
could have employed another catecholaminergic agonist
compound other than methylphenidate to validate find-
ings. Thirdly, the generalizability of this feasibility trial
might be lacking because it did not include motor and
functional metrics to complement present neurocogni-
tive metrics. Related to assessment, this feasibility trial
has embarked to quantify the presence of mild cognitive
impairment using IQCODE. In addition to controversies
on what constitutes mild cognitive impairment [82],
IQCODE lacks the vigor of the other bedside measures
such as Montreal Cognitive Assessment (MoCA) and
Mini-Mental State Examination (MMSE) for soliciting
the presence of cognitive decline but there are dissenting
views [31, 83]. IQCODE has been validated in the Arabic
speaking population and appears to have good psycho-
metric properties [31, 33, 34]. Future studies should
employed other conventional neuropsychological mea-
sures to tap into the presence of mild cognitive impair-
ment. Other than IQCODE, the present feasibility trial
has utilized strong non-verbal components or those that
have been employed in the Arabic-speaking population
previously. With a few exceptions, the majority of the
measures do not have cutoffs for the TBI population in
Oman. For these reasons, protracted exercises were
taken to establish ‘caseness’ for executive dysfunction.
For these reasons, ‘caseness’ for executive dysfunction
was derived from the z-values (− 1.5) or percentile = <
7th) as previously reported elsewhere [29]. Fourthly, it
might be theoretically interesting to include another co-
hort of TBI rather than those with executive functioning.
This might increase the scientific merit of the current
feasibility trial. Fifthly, in Oman, the demography is
characterized by a pyramidal-like population structure
with the majority as a youth. Indeed, the previous survey
in Oman has indicated that the majority of the victim of
the road traffic accident and TBI are youngster [84]. In a
population of younger TBI patients as the present co-
hort, it likely that noted ‘improvements’ could stem from
many factors including placebo effect, spontaneous re-
covery, and/ or developmental changes as the brain is
well established to continue growth until ~ age 25. The
present study, open-label, was not equipped to circum-
vent these confounders. Additional studies using a vigor-
ous research methodology are needed to shed further
light on the trajectory between time since injury, neuro-
psychological recovery, and the impact of a number of
commonly used pharmacological agents on brain-
injured populations.
Conclusions
Despite traumatic brain injury being a global challenge, is-
sues pertinent to the disability it triggers and the rehabili-
tation that is needed in emerging economies, such as
Oman, have received scant attention in past literature.
The present study utilized a feasibility trial to explore
whether treatment with methylphenidate, in patients with
TBI, would improve executive functioning. The investiga-
tion was uncontrolled, open label design. The study results
suggested that methylphenidate tended to positively im-
pact executive functioning. The study outcome also sug-
gested that noted improvement was most heavily dictated
by time elapsed since the injury. Unlike prior research,
there was no gender difference in executive functioning or
response to treatment. An unpredicted finding in the
present study was that improvements did not reverse fol-
lowing drug withdrawal among those patients operational-
ized in the “chronic” group. Being a feasibility trial, it is
important for future studies to scrutinize these present
findings through a study design with a more robust meth-
odology. Finally, we believe this is an important feasibility
study in this population. In the future, we want to extend
this work into randomized controlled trial (RCT) to ad-
dress limitations, strengthen findings that supports the
conclusion and confirmation of methylphenidate treat-
ment. This evidence-based research is valuable to both
public health officials and policy decision-makers in order
to design and implement policies that improve health and
social outcomes.
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